Novocure | search
Click here to view Novocure news from 60+ newspapers.
Bookmark or Share- NovoCure Ltd (NVCR) Q1 2024 Earnings: Revenue Surpasses Estimates ...NovoCure reported quarterly net revenues of $138.5 million, a 13% increase from $122.2 million in the same period last year, surpassing the estimated revenue of $131.45 million. This growth was ...
- Novocure Press Releases | Latest NVCR NewsNovocure to Report First Quarter 2024 Financial Results. ROOT, Switzerland– (BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open.
- Novocure | cancer therapy: Tumor Treating Fields (TTFields)Novocure (NASDAQ: NVCR) is an oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields.
- Novocure | making a difference in cancer | NVCR company infoNovocure is a global oncology company striving to extend survival in aggressive forms of cancer with our innovative Tumor Treating Fields (TTFields) therapy.
- Novocure Announces Presentations on Tumor Treating Fields Therapy ...ROOT, Switzerland– (BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 2023 ...
More
